Humanigen Inc (HGENQ)

[cowtown jay]

"I track SEC filings everyday for Humanigen, Baudax, Gracell, and Novavax." Progress report.

Now, Form 25-NSE filings have been made for three of the above companies, to remove their stock from listing on the Nasdaq.

We know that news has now been reported for Novavax and Gracell.

Novavax:

"Novavax settles dispute with international vaccine group Gavi
By Michael Erman
February 22, 20249:43 AM CST

Shares of the company rose 23.2% to $4.91 on Thursday.
Its stock has dropped nearly 60% since the company last year raised doubts about its ability to remain in business. Nearly half of Novavax's free float shares were in short position, as of Jan. 31."

https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-settles-dispute-with-international-vaccine-group-gavi-2024-02-22/

Noteworthy are the recent beneficial ownership filings.

https://www.sec.gov/cgi-bin/browse-edgar?company=novavax&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany

https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1000694/000110465924026225/tm246954d1_8k.htm

Gracell:

"SAN DIEGO and SUZHOU, China and SHANGHAI, China, February 22, 2024 -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the “Merger Agreement”), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales (“Parent”), and Grey Wolf Merger Sub (“Merger Sub”), an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent. The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”). As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent."

https://www.sec.gov/Archives/edgar/data/1826492/000110465924026350/tm246846d1_ex99-1.htm

And again, we see a number of recently filed beneficial ownership statements for Gracell.

https://www.sec.gov/cgi-bin/browse-edgar?company=gracell&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany

I think the efficacy of both Gracell's CAR-T, and the Novavax prototype vaccine, may prove to have been greatly enhanced by using lenzilumab in those applications. We haven't seen evidence of that yet. However, we certainly saw game-changing enhancement of CMML treatment using lenz in the PREACH-M study.

"MedicalResearch.com: What are the next steps in this study?

Response: The PREACH-M trial is a phase 2/3 trial. We plan to unveil new data showing comprehensive clinical responses according to established criteria, somatic mutation frequencies and bone marrow plasma inflammatory cytokine levels at international meetings later this year.

Humanigen and SAHMRI are assessing regulatory pathways that may enable early results to support a regulatory submission and potential provisional registration or approval by the Therapeutic Goods Administration in Australia. We are also considering opening up PREACH-M, or a similar study in other countries such as the UK and the US, subject to resourcing and Humanigen’s corporate strategy."

https://medicalresearch.com/cancer-_-oncology/preach-m-trial-humanigen-study-evaluates-lenzilumab-and-azacitidine-for-cmml/#:~:text=The%20preliminary%20results%20from%20the,cells%20with%20RAS%2Dpathway%20mutations.

Still in progress are developments regarding Baudax/Tera-Immune, and Humanigen/Taran.